Formulary Watch

Articles

FDA Accepts NDA for Zuranolone for Depression

February 06, 2023

Zuranolone is a rapid-acting neuroactive steroid that can take effect in 14 days to treat patients with major depressive disorder and postpartum depression. The FDA has assigned a PDUFA action date of Aug. 5, 2023.